Impact of Hormone Therapy Side Effects on Health-related Quality of Life, Distress, and Well-being of Breast Cancer Survivors

Overview

Journal Sci Rep

Specialty Science

Date 2022 Nov 5

PMID 36333362

Authors

Y Andreu

A Soto-Rubio

M Ramos-Campos

A Escriche-Saura

M Martinez

J Gavila

Affiliations

Soon will be listed here.

Abstract

To explore the modulatory role of Adjuvant Hormone Therapy (AHT) on health-related quality of life (QoL), subjective well-being and distress prevalence in Breast Cancer (BC) survivors, considering the survival phase. Cross-sectional study with control group. 616 BC survivors participated. Examination of interaction effect between AHT and time since end of primary treatment showed that many of the positive changes observed through the survival phases were experienced exclusively by survivors without AHT. When AHT was not prescribed, longer time elapsed was associated with a decrease in distress prevalence and an improvement in subjective well-being and QoL. It seems there is a turning point around the fifth year after finalization of primary treatment, from which the survivors without AHT significantly improve in several areas and those with AHT do so to a lesser extent. It is expected that the improvement in QoL throughout the different survival phases will have a significant impact on the adherence and maintenance of AHT and, consequently, the likelihood of survival. Thus, AHT side-effects should be routinely assessed by health care providers to gain accurate knowledge that allows improving the QoL of BC survivors.

Citing Articles

Integrating RNA-seq and scRNA-seq to explore the prognostic features and immune landscape of exosome-related genes in breast cancer metastasis.

Huang G, Yu Y, Su H, Gan H, Chu L Ann Med. 2025; 57(1):2447917.

PMID: 39847423 PMC: 11758802. DOI: 10.1080/07853890.2024.2447917.

Impact of a Physical Exercise and Health Education Program on Metabolic Syndrome and Quality of Life in Postmenopausal Breast Cancer Women Undergoing Adjuvant Treatment with Aromatase Inhibitors.

Cespedes P, Martinez-Arnau F, Torregrosa M, Cauli O, Buigues C Medicina (Kaunas). 2024; 60(11).

PMID: 39597078 PMC: 11596674. DOI: 10.3390/medicina60111893.

Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study.

Acs B, Hartman J, Sonmez D, Lindman H, Johansson A, Fredriksson I Lancet Reg Health Eur. 2024; 40:100886.

PMID: 38745990 PMC: 11092884. DOI: 10.1016/j.lanepe.2024.100886.

Effects of a Phone-Based Support Program for Women With Breast Cancer Undergoing Chemotherapy: A Pilot Study.

Chen X, Chaimongkol N, Hengudomsub P SAGE Open Nurs. 2024; 10:23779608241231176.

PMID: 38415216 PMC: 10898293. DOI: 10.1177/23779608241231176.

A Comprehensive Review on Electrochemical Nano Biosensors for Precise Detection of Blood-Based Oncomarkers in Breast Cancer.

Sadeghi M, Sadeghi S, Naghib S, Garshasbi H Biosensors (Basel). 2023; 13(4).

PMID: 37185556 PMC: 10136762. DOI: 10.3390/bios13040481.

References

Fallowfield L, Jenkins V . Psychosocial/survivorship issues in breast cancer: are we doing better?. J Natl Cancer Inst. 2014; 107(1):335. DOI: 10.1093/jnci/dju335. View

Peters E, Mendoza Schulz L, Reuss-Borst M . Quality of life after cancer-How the extent of impairment is influenced by patient characteristics. BMC Cancer. 2016; 16(1):787. PMC: 5057271. DOI: 10.1186/s12885-016-2822-z. View

. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001):1341-1352. DOI: 10.1016/S0140-6736(15)61074-1. View

Wahba H, El-Hadaad H . Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015; 12(2):106-16. PMC: 4493381. DOI: 10.7497/j.issn.2095-3941.2015.0030. View

Brauer E, Ganz P, Pieters H . "Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment. J Oncol Pract. 2016; 12(12):e991-e1000. PMC: 5455585. DOI: 10.1200/JOP.2016.011767. View

Lambert L, Balneaves L, Howard A, Chia S, Gotay C . Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. BMC Cancer. 2018; 18(1):732. PMC: 6042363. DOI: 10.1186/s12885-018-4644-7. View

Cahir C, Guinan E, Dombrowski S, Sharp L, Bennett K . Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: A systematic review and meta-analysis. Patient Educ Couns. 2015; . DOI: 10.1016/j.pec.2015.05.013. View

Peddie N, Agnew S, Crawford M, Dixon D, MacPherson I, Fleming L . The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis. Breast. 2021; 58:147-159. PMC: 8165559. DOI: 10.1016/j.breast.2021.05.005. View

Brito C, Portela M, de Vasconcellos M . Factors associated to persistence with hormonal therapy in women with breast cancer. Rev Saude Publica. 2014; 48(2):284-95. PMC: 4206152. DOI: 10.1590/s0034-8910.2014048004799. View

10.

Gross J . Antecedent- and response-focused emotion regulation: divergent consequences for experience, expression, and physiology. J Pers Soc Psychol. 1998; 74(1):224-37. DOI: 10.1037//0022-3514.74.1.224. View

11.

Friese C, Pini T, Li Y, Abrahamse P, Graff J, Hamilton A . Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat. 2013; 138(3):931-9. PMC: 3633703. DOI: 10.1007/s10549-013-2499-9. View

12.

Beckwee D, Leysen L, Meuwis K, Adriaenssens N . Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer. 2017; 25(5):1673-1686. DOI: 10.1007/s00520-017-3613-z. View

13.

Heins M, de Ligt K, Verloop J, Siesling S, Korevaar J . Adverse health effects after breast cancer up to 14 years after diagnosis. Breast. 2021; 61:22-28. PMC: 8661054. DOI: 10.1016/j.breast.2021.12.001. View

14.

Humphries B, Collins S, Guillaumie L, Lemieux J, Dionne A, Provencher L . Women's Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions. Pharmacy (Basel). 2018; 6(2). PMC: 6024955. DOI: 10.3390/pharmacy6020053. View

15.

Franzoi M, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I . Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021; 22(7):e303-e313. DOI: 10.1016/S1470-2045(20)30666-5. View

16.

Amir E, Seruga B, Niraula S, Carlsson L, Ocana A . Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011; 103(17):1299-309. DOI: 10.1093/jnci/djr242. View

17.

Street Jr R, Makoul G, Arora N, Epstein R . How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns. 2009; 74(3):295-301. DOI: 10.1016/j.pec.2008.11.015. View

18.

Kimmick G, Edmond S, Bosworth H, Peppercorn J, Marcom P, Blackwell K . Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast. 2015; 24(5):630-6. PMC: 4824055. DOI: 10.1016/j.breast.2015.06.010. View

19.

Wells K, Pan T, Vazquez-Otero C, Ung D, Ustjanauskas A, Munoz D . Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer. 2016; 24(10):4123-30. PMC: 4995114. DOI: 10.1007/s00520-016-3229-8. View

20.

Hechtner M, Krause M, Konig J, Appold S, Hornemann B, Singer S . Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial. Radiother Oncol. 2017; 126(2):283-290. DOI: 10.1016/j.radonc.2017.12.005. View